Optimization of the driver's seat belt and injury biomechanical analysis in real-world minivan small offset impact accident scenarios

被引:0
|
作者
Yang, Xiuju [1 ]
Shi, Jingjing [2 ]
Fu, Qianying [2 ]
Pu, Shanshan [2 ]
Lian, Chunxiao [2 ]
Li, Kui [3 ]
Yin, Zhiyong [1 ,4 ]
Liu, Shengxiong [2 ]
Wang, Guixue [1 ]
机构
[1] Chongqing Univ, State & Local Joint Engn Lab Vasc Implants, Key Lab Biorheol Sci & Technol, Coll Bioengn,Minist Educ, Chongqing, Peoples R China
[2] Chongqing Univ Technol, Dept Biomed Engn, Coll Pharm & Bioengn, Chongqing, Peoples R China
[3] Army Med Univ, Chongqing Key Lab Vehicle Crash Bioimpact & Traff, Dept 4, Inst Surg Res,Daping Hosp, Chongqing, Peoples R China
[4] China Automot Engn Res Inst Co Ltd, Chongqing, Peoples R China
关键词
small offset collision; accident reconstruction; driver injury; pre-tensioned force-limiting seat belt; multi-objective genetic algorithm; biomechanics analysis; genetic algorithm; SIMULATION; VEHICLE; DESIGN;
D O I
10.3389/fbioe.2022.965206
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
To minimize injuries and protect the safety of the driver in minivan small offset collisions, an optimized pre-tensioned force-limiting seat belt was proposed herein. An accident with detailed information, such as medical reports, vehicle inspection reports, and accident scene photographs, was reconstructed using HyperMesh software. The effectiveness of both the accident model and the pre-tensioned force-limiting seat belt was evaluated. To obtain the optimal seat belt parameters for driver protection, first, force-limiting A, pre-tensioned force B, and pre-tensioned time C factors were selected in designing an orthogonal test with different factor levels. The influence laws of each factor on the injury biomechanical characteristics of the driver were analyzed via the direct analysis method. Moreover, each kind of critical injury value of the human body was synthesized, and the radial basis function surrogate model was constructed. The three seat belt parameters were optimized using the NSGA-II multi-objective genetic algorithm. The results showed that the optimal balance variable parameter of the seat belt was 4751.618 N-2451.839 N-17.554 ms (A-B-C). Finally, the optimal scheme was verified in a system simulating a minivan small offset collision. The results showed that after optimization, the skull von Mises stress was reduced by 36.9%, and the stress of the cervical vertebra cortical bone and cancellous bone decreased by 29.1% and 30.8%, respectively. In addition, the strains of the ribs and lungs decreased by 31.2% and 30.7%, respectively.
引用
收藏
页数:17
相关论文
共 29 条
  • [21] Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy
    Bodor, J. Nicholas
    Bauman, Jessica R.
    Handorf, Elizabeth A.
    Ross, Eric A.
    Clapper, Margie L.
    Treat, Joseph
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (05) : 1755 - 1763
  • [22] Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations
    Harvey, R. Donald
    Bruinooge, Suanna S.
    Chen, Li
    Garrett-Mayer, Elizabeth
    Rhodes, Whitney
    Stepanski, Edward
    Uldrick, Thomas S.
    Ison, Gwynn
    Khozin, Sean
    Rubinstein, Wendy S.
    Schenkel, Caroline
    Miller, Robert S.
    Komatsoulis, George A.
    Schilsky, Richard L.
    Kim, Edward S.
    CLINICAL CANCER RESEARCH, 2021, 27 (09) : 2430 - 2434
  • [23] Real-world data on next-generation sequencing using comprehensive genomic profiling assays for detecting driver oncogenes in advanced non-small cell lung cancer: Analysis with the National Database of Japan
    Masaki, I.
    Iwasaku, M.
    Morita, R.
    Doi, T.
    Ishikawa, T.
    Ogura, Y.
    Kawachi, H.
    Katayama, Y.
    Nishioka, N.
    Morimoto, K.
    Tokuda, S.
    Yamada, T.
    Kohichi, T.
    ANNALS OF ONCOLOGY, 2023, 34
  • [24] "Living with Lymphoma", a real-world patient-reported outcome Analysis to evaluate the physical, mental, social, and personal Impact of aggressive Non-Hodgkin's Lymphoma Disease
    Wurm-Kuczera, R.
    Hohloch, K.
    Pawlowski, F.
    Poeschel, V
    Ziepert, M.
    Schmitz, N.
    Chapuy, B.
    Wulf, G.
    Truemper, L.
    Freund, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 191 - 191
  • [25] Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World
    Pasello, Giulia
    Lorenzi, Martina
    Scattolin, Daniela
    Del Conte, Alessandro
    Cecere, Fabiana
    Pavan, Alberto
    Macerelli, Marianna
    Polo, Valentina
    Pilotto, Sara
    Santarpia, Mariacarmela
    Cumerlato, Enrico
    Da Ros, Valentina
    Targato, Giada
    Bortolami, Alberto
    Bonanno, Laura
    Ferro, Alessandra
    Dal Maso, Alessandro
    Frega, Stefano
    Guarneri, Valentina
    ONCOLOGIST, 2024, 29 (07): : 596 - 608
  • [26] Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers
    Ayers, Kristin L.
    Mullaney, Tommy
    Zhou, Xiang
    Liu, Jane J.
    Lee, Kyeryoung
    Ma, Meng
    Jones, Scott
    Li, Li
    Redfern, Arielle
    Jappe, Whitney
    Liu, Zongzhi
    Goldsweig, Howard
    Yadav, Kamlesh K.
    Hahner, Nicholas
    Dietz, Matthew
    Zimmerman, Michelle
    Prentice, Tony
    Newman, Scott
    Veluswamy, Rajwanth
    Wisnivesky, Juan
    Hirsch, Fred R.
    Oh, William K.
    Li, Shuyu D.
    Schadt, Eric E.
    Chen, Rong
    ONCOLOGIST, 2021, 26 (07): : E1226 - E1239
  • [27] Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1
    Uryu, Kiyoaki
    Imamura, Yoshinori
    Shimoyama, Rai
    Mase, Takahiro
    Fujimura, Yoshiaki
    Hayashi, Maki
    Ohtaki, Megu
    Otani, Keiko
    Hibino, Makoto
    Horiuchi, Shigeto
    Fukui, Tomoya
    Fukai, Ryuta
    Chihara, Yusuke
    Iwase, Akihiko
    Yamada, Noriko
    Tamura, Yukihiro
    Harada, Hiromasa
    Shinozaki, Nobuaki
    Shimada, Toyoshi
    Tsuya, Asuka
    Fukuoka, Masahiro
    Minami, Hironobu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (02) : 197 - 208
  • [28] Real-world analysis of the impact of pemetrexed in firstline maintenance (1LM) with immunotherapy (IO) for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic
    Fabio, Gomes
    Niall, Gilding
    Vivian, Tan
    Katerina, Christoforou
    Joanne, Rule
    Amine, Aziez
    Adam, Januszewski
    Anna, Minchom
    LUNG CANCER, 2024, 190 : 52 - 52
  • [29] Real-world analysis of the impact of pemetrexed in firstline maintenance (1LM) with immunotherapy (IO) for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic
    Gomes, Fabio
    Gilding, Niall
    Tan, Vivian
    Christoforou, Katerina
    Rule, Joanne
    Aziez, Amine
    Januszewski, Adam
    Minchom, Anna
    LUNG CANCER, 2024, 190